Toward noninvasive genomic screening of lung cancer patients

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2589-2591

  Sequist, Lecia V ^a   Engelman, Jeffrey A ^a   Lynch, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; DNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

CANCER SCREENING; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; EDITORIAL; EGFR GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENOMICS; HUMAN; LUNG NON SMALL CELL CANCER; MET GENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BLOOD; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC SCREENING; GENETICS; LUNG TUMOR; MASS SCREENING; METHODOLOGY; MUTATION; NOTE; PATHOLOGY; PATIENT SELECTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC SCREENING; HUMANS; LUNG NEOPLASMS; MASS SCREENING; MUTATION; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 66849143180     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.4875     Document Type: Editorial

References (31)

1. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
2. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
3. Mok T, Wu Y-L, Thongprasert S, et al: Phase III, randomised, open-label, firstline study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (IPASS). The 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, September 12-16, 2008
4. Sequist LV, Bell DW, Lynch TJ, et al: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595, 2007
5. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
6. Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed 2:e73, 2005
7. Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitorsensitive and -resistant EGFR mutants. PLoS Med 2:e313, 2005
8. Cappuzzo F, Ligorio C, Janne PA, et al: Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/ phospho-Aktpositive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL trial. J Clin Oncol 25:2248-2255, 2007
9. Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007
10. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937, 2007
11. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
12. Bell DW, Haber DA: A blood-based test for epidermal growth factor receptor mutations in lung cancer. Clin Cancer Res 12:3875-3877, 2006
13. Horiike A, Kimura H, Nishio K, et al: Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest 131:1628-1634, 2007
14. Pao W, Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: Searching for the ideal method. Clin Cancer Res 13:4954-4955, 2007
15. Sequist LV, Joshi VA, Janne PA, et al: Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 12:4403s-4408s, 2006
16. Bai H, Mao L, Wang HS, et al: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stage IIIB to IV non-small-cell lung cancer. J Clin Oncol 27:2653-2659, 2009
17. Janne PA, Borras AM, Kuang Y, et al: A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res 12:751-758, 2006
18. Cohen V, Agulnik JS, Jarry J, et al: Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer 107:2858-2865, 2006
19. Chin TM, Anuar D, Soo R, et al: Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem 53:62-70, 2007
20. Mitsudomi T, Kosaka T, Endoh H, et al: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520, 2005
21. Taron M, Ichinose Y, Rosell R, et al: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-5885, 2005
22. Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
23. Douillard JY, Hirsh V, Mok T, et al: Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol 26:424s, 2008 (suppl; abstr 8001)
24. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-smallcell lung cancer. Clin Cancer Res 12:3915-3921, 2006
25. Kimura H, Suminoe M, Kasahara K, et al: Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97:778-784, 2007
26. Moran T, Pas-Ares L, Isla D, et al: High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients with poor performance status (PS). J Clin Oncol 25:386s, 2007 (suppl; abstr 7505)
27. Nagrath S, Sequist LV, Maheswaran S, et al: Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:1235-1239, 2007
28. Maheswaran S, Sequist LV, Nagrath S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-377, 2008
29. Inoue A, Suzuki T, Fukuhara T, et al: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346, 2006
30. Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95:998-1004, 2006
31. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al: A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24:369s, 2006 (suppl; abstr 7020)